Don’t use Promacta for patients with chronic liver disease

On May 2, the U.S. Food and Drug Administration and GlaxoSmithKline reminded health professionals not to use Promacta (eltromobopag) for the treatment of thrombocytopenia in patients with chronic liver disease. Read more at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm211796.htm.

LEAVE A REPLY

Please enter your comment!
Please enter your name here